CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
three times weekly Epo +1 moredrug
Likely dose
three times weekly Epo 400 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01235923
NCT01235923Phase 2Completed
CompareCT.gov

A Randomized, Masked Study of Weekly Erythropoietin Dosing in Preterm Infants

University of New Mexico·interventional·Posted Nov 8, 2010·Updated Jun 21, 2022

In Brief

A Phase 2 clinical trial evaluating three times weekly Epo and weekly Epo for Preterm Infants. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Preterm infants are a risk for multiple transfusions, and the administration of human recombinant erythropoietin (Epo) has been shown to decrease transfusion requirements. Dosing usually occurs three times a week, but extended dosing schedules have been successful in adults. The investigators assessed weekly Epo dosing in preterm infants compared to standard three times weekly dosing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPreterm Infants
CountriesUnited States
CollaboratorsNational Center for Research Resources (NCRR)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 8, 2010
Enrollment StartApr 1, 2006
Primary CompletionMar 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 15.7 years ago

Interventions

three times weekly Epodrug

Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks

weekly Epodrug

Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks